1
40
5
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1007/s10637-009-9332-7" target="_blank" rel="noreferrer noopener">http://doi.org/10.1007/s10637-009-9332-7</a>
Pages
380–391
Issue
2
Volume
29
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma.
Publisher
An entity responsible for making the resource available
Investigational new drugs
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011-04
Subject
The topic of the resource
*Chemoprevention; Analysis of Variance; Animal; Animal Studies; Animal/drug effects; Animals; Antioxidants; Behavior; Blotting; Carcinoma; Cardiotoxicity; Cardiotoxins/*toxicity; Chemoprevention; Data Analysis Software; Descriptive Statistics; Disease Models; Doppler; Dose-Response Relationship; Drug; Echocardiography; Feeding Behavior/drug effects; Female; Fisher's Exact Test; Funding Source; Heart – Drug Effects; Heart/drug effects/physiopathology; Hepatocellular – Prevention and Control; Hepatocellular/*drug therapy/pathology/physiopathology; Hepatocytes/drug effects/pathology; Humans; Liver Neoplasms/*drug therapy/pathology/physiopathology; Liver/drug effects/pathology/physiopathology; Polyphenols – Therapeutic Use; Rats; Resveratrol; Sprague-Dawley; Stilbenes/*therapeutic use; Systole/drug effects; Western
Creator
An entity primarily responsible for making the resource
Luther Daniel J; Ohanyan Vahagn; Shamhart Patricia E; Hodnichak Cheryl M; Sisakian Hamayak; Booth Tristan D; Meszaros J Gary; Bishayee Anupam
Description
An account of the resource
Hepatocellular carcinoma (HCC), one of the most lethal cancers, results in more than one million fatalities worldwide every year. In view of the limited therapeutic alternatives and poor prognosis of liver cancer, preventive control approaches, notably chemoprevention, have been considered to be the best strategy in lowering the present prevalence of the disease. Resveratrol, a naturally occurring antioxidant and antiinflammatory agent found in grapes and red wine, inhibits carcinogenesis with a pleiotropic mode of action. Recently, we have reported that dietary resveratrol significantly prevents chemically-induced liver tumorigenesis in rats. One of the mechanisms of resveratrol-mediated chemoprevention of hepatocarcinogenesis could be related to its antiinflammatory action through hepatic cyclooxygenase (COX-2) inhibition. Although several COX-2 inhibitors are known to exert chemopreventive efficacy, not all are considered ideal candidates for chemoprevention due to the risk of adverse cardiovascular events. Accordingly, the objective of the present study was to evaluate the role of resveratrol on cardiac performance during experimental hepatocarcinogenesis initiated with diethylnitrosamine and promoted by phenobarbital. Rats had free access to diet supplemented with resveratrol four weeks before the carcinogen injection and 14 weeks thereafter. The cardiotoxicity of resveratrol was assessed by monitoring the cardiac function using transthoracic echocardiography as well as Western blot analysis of cardiac tissue. Long-term dietary administration of resveratrol dose-dependently suppressed hepatic tumor multiplicity, the principal endpoint for evaluating the chemopreventive potential of a candidate agent. The chemopreventive effects of resveratrol were also reflected in histopathological assessment of hepatic tissues. Resveratrol did not exhibit any cardiotoxicity but rather improved the cardiac function in a dose-responsive fashion. Our results indicate that resveratrol-mediated chemoprevention of rat liver carcinogenesis is devoid of any adverse cardiovascular events. Resveratrol may be developed as a chemopreventive as well as therapeutic drug for human HCC.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1007/s10637-009-9332-7" target="_blank" rel="noreferrer noopener">10.1007/s10637-009-9332-7</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Chemoprevention
2011
Analysis of Variance
Animal
Animal Studies
Animal/drug effects
Animals
Antioxidants
Behavior
Bishayee Anupam
Blotting
Booth Tristan D
Carcinoma
Cardiotoxicity
Cardiotoxins/*toxicity
Chemoprevention
Data Analysis Software
Department of Integrative Medical Sciences
Descriptive Statistics
Disease Models
Doppler
Dose-Response Relationship
Drug
Echocardiography
Feeding Behavior/drug effects
Female
Fisher's Exact Test
Funding Source
Heart – Drug Effects
Heart/drug effects/physiopathology
Hepatocellular – Prevention and Control
Hepatocellular/*drug therapy/pathology/physiopathology
Hepatocytes/drug effects/pathology
Hodnichak Cheryl M
Humans
Investigational new drugs
Liver Neoplasms/*drug therapy/pathology/physiopathology
Liver/drug effects/pathology/physiopathology
Luther Daniel J
Meszaros J Gary
NEOMED College of Medicine
Ohanyan Vahagn
Polyphenols – Therapeutic Use
Rats
Resveratrol
Shamhart Patricia E
Sisakian Hamayak
Sprague-Dawley
Stilbenes/*therapeutic use
Systole/drug effects
Western
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1007/s11095-010-0144-4" target="_blank" rel="noreferrer noopener">http://doi.org/10.1007/s11095-010-0144-4</a>
Pages
1080–1091
Issue
6
Volume
27
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis.
Publisher
An entity responsible for making the resource available
Pharmaceutical research
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-06
Subject
The topic of the resource
Animals; Anticarcinogenic Agents/*therapeutic use; Chemoprevention; Cyclooxygenase 2/immunology; Diethylnitrosamine; Female; HSP70 Heat-Shock Proteins/immunology; Humans; Inflammation/prevention & control; Liver Neoplasms/chemically induced/*immunology/*prevention & control; Liver/drug effects/pathology; NF-kappa B/immunology; Rats; Resveratrol; Sprague-Dawley; Stilbenes/*therapeutic use
Creator
An entity primarily responsible for making the resource
Bishayee Anupam; Waghray Abhijeet; Barnes Kendra F; Mbimba Thomas; Bhatia Deepak; Chatterjee Malay; Darvesh Altaf S
Description
An account of the resource
PURPOSE: Resveratrol, present in grapes and red wine, has been found to prevent diethylnitrosamine (DENA)-initiated rat liver tumorigenesis, though the chemopreventive mechanisms are not completely elucidated. The current study was designed to explore whether the antiinflammatory properties of resveratrol play a role in its antihepatocarcinogenic action. METHODS: Liver samples were harvested from a 20-week chemopreventive study in which resveratrol (50, 100 and 300 mg/kg) was shown to inhibit DENA-induced hepatocyte nodules in Sprague-Dawley rats in a dose-responsive manner. Hepatic preneoplastic and inflammatory markers, namely heat shock protein (HSP70), cyclooxygenase-2 (COX-2) and nuclear factor-kappaB (NF-kappaB), were studied using immunohistochemical as well as Western blot techniques. RESULTS: Resveratrol dose-dependently suppressed DENA-induced increased expressions of hepatic HSP70 and COX-2. Resveratrol also attenuated the
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1007/s11095-010-0144-4" target="_blank" rel="noreferrer noopener">10.1007/s11095-010-0144-4</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2010
Animals
Anticarcinogenic Agents/*therapeutic use
Barnes Kendra F
Bhatia Deepak
Bishayee Anupam
Chatterjee Malay
Chemoprevention
Cyclooxygenase 2/immunology
Darvesh Altaf S
Department of Pharmaceutical Sciences
Diethylnitrosamine
Female
HSP70 Heat-Shock Proteins/immunology
Humans
Inflammation/prevention & control
Liver Neoplasms/chemically induced/*immunology/*prevention & control
Liver/drug effects/pathology
Mbimba Thomas
NEOMED College of Pharmacy
NF-kappa B/immunology
Pharmaceutical research
Rats
Resveratrol
Sprague-Dawley
Stilbenes/*therapeutic use
Waghray Abhijeet
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.ctrv.2009.10.002" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.ctrv.2009.10.002</a>
Pages
43–53
Issue
1
Volume
36
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma.
Publisher
An entity responsible for making the resource available
Cancer treatment reviews
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-02
Subject
The topic of the resource
Anticarcinogenic Agents/*therapeutic use; Antineoplastic Agents – Therapeutic Use; Carcinoma; Hepatocellular – Drug Therapy; Hepatocellular – Prevention and Control; Hepatocellular/*drug therapy/*prevention & control; Humans; Liver Neoplasms – Drug Therapy; Liver Neoplasms – Prevention and Control; Liver Neoplasms/*drug therapy/*prevention & control; Resveratrol; Stilbenes – Therapeutic Use; Stilbenes/*therapeutic use
Creator
An entity primarily responsible for making the resource
Bishayee Anupam; Politis Themos; Darvesh Altaf S
Description
An account of the resource
Hepatocellular carcinoma (HCC) is one of the most common cancers and lethal diseases in the world. Although the majority of HCC cases occur in developing countries of Asia and Africa, the prevalence of liver cancer has risen considerably in Japan, Western Europe as well as the United States. HCC most commonly develops in patients with chronic liver disease, the etiology of which includes viral hepatitis (B and C), alcohol, obesity, iron overload and dietary carcinogens, including aflatoxins and nitrosamines. The current treatment modalities, including surgical resection and liver transplantation, have been found to be mostly ineffective. Hence, there is an obvious critical need to develop alternative strategies for the chemoprevention and treatment of HCC. Oxidative stress as well as inflammation has been implicated in the development and progression of hepatic neoplasia. Using naturally occurring phytochemicals and dietary compounds endowed with potent antioxidant and antiinflammatory properties is a novel approach to prevent and control HCC. One such compound, resveratrol, present in grapes, berries, peanuts as well as red wine, has emerged as a promising molecule that inhibits carcinogenesis with a pleiotropic mode of action. This review examines the current knowledge on mechanism-based in vitro and in vivo studies on the chemopreventive and chemotherapeutic potential of resveratrol in liver cancer. Pre-clinical and clinical toxicity studies as well as pharmacokinetic data of resveratrol have also been highlighted in this review. Future directions and challenges involved in the use of resveratrol for the prevention and treatment of HCC are also discussed.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.ctrv.2009.10.002" target="_blank" rel="noreferrer noopener">10.1016/j.ctrv.2009.10.002</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2010
Anticarcinogenic Agents/*therapeutic use
Antineoplastic Agents – Therapeutic Use
Bishayee Anupam
Cancer treatment reviews
Carcinoma
Darvesh Altaf S
Department of Pharmaceutical Sciences
Hepatocellular – Drug Therapy
Hepatocellular – Prevention and Control
Hepatocellular/*drug therapy/*prevention & control
Humans
Liver Neoplasms – Drug Therapy
Liver Neoplasms – Prevention and Control
Liver Neoplasms/*drug therapy/*prevention & control
NEOMED College of Pharmacy
Politis Themos
Resveratrol
Stilbenes – Therapeutic Use
Stilbenes/*therapeutic use
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.juro.2013.09.104" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.juro.2013.09.104</a>
Pages
1584–1585
Issue
5
Volume
191
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Editorial comment.
Publisher
An entity responsible for making the resource available
The Journal of urology
Date
A point or period of time associated with an event in the lifecycle of the resource
2014
2014-05
Subject
The topic of the resource
Animals; Antioxidants/*therapeutic use; Male; Resveratrol; Spermatic Cord Torsion/*surgery; Stilbenes/*therapeutic use
Creator
An entity primarily responsible for making the resource
McMahon Dan
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.juro.2013.09.104" target="_blank" rel="noreferrer noopener">10.1016/j.juro.2013.09.104</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2014
Animals
Antioxidants/*therapeutic use
Male
McMahon Dan
Resveratrol
Spermatic Cord Torsion/*surgery
Stilbenes/*therapeutic use
The Journal of urology
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1158/1940-6207.CAPR-08-0160" target="_blank" rel="noreferrer noopener">http://doi.org/10.1158/1940-6207.CAPR-08-0160</a>
Pages
409–418
Issue
5
Volume
2
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials.
Publisher
An entity responsible for making the resource available
Cancer prevention research (Philadelphia, Pa.)
Date
A point or period of time associated with an event in the lifecycle of the resource
2009
2009-05
Subject
The topic of the resource
Animals; Antineoplastic Agents/*therapeutic use; Clinical Trials as Topic; Humans; Neoplasms/*prevention & control; Resveratrol; Stilbenes/*therapeutic use
Creator
An entity primarily responsible for making the resource
Bishayee Anupam
Description
An account of the resource
Resveratrol (3,4',5-trihydroxy-trans-stilbene) is a dietary polyphenol derived from grapes, berries, peanuts, and other plant sources. During the last decade, resveratrol has been shown to possess a fascinating spectrum of pharmacologic properties. Multiple biochemical and molecular actions seem to contribute to resveratrol effects against precancerous or cancer cells. Resveratrol affects all three discrete stages of carcinogenesis (initiation, promotion, and progression) by modulating signal transduction pathways that control cell division and growth, apoptosis, inflammation, angiogenesis, and metastasis. The anticancer property of resveratrol has been supported by its ability to inhibit proliferation of a wide variety of human tumor cells in vitro. These in vitro data have led to numerous preclinical animal studies to evaluate the potential of this drug for cancer chemoprevention and chemotherapy. This review provides concise, comprehensive data from preclinical in vivo studies in various rodent models of human cancers, highlighting the related mechanisms of action. Bioavailability, pharmacokinetic, and potential toxicity studies of resveratrol in humans and ongoing interventional clinical trials are also presented. The conclusion describes directions for future resveratrol research to establish its activity and utility as a human cancer preventive and therapeutic drug.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1158/1940-6207.CAPR-08-0160" target="_blank" rel="noreferrer noopener">10.1158/1940-6207.CAPR-08-0160</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2009
Animals
Antineoplastic Agents/*therapeutic use
Bishayee Anupam
Cancer prevention research (Philadelphia, Pa.)
Clinical Trials as Topic
Humans
Neoplasms/*prevention & control
Resveratrol
Stilbenes/*therapeutic use